NCT01435278

Efficacy and Safety of Glucosanol in Maintaining Body Weight

Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: InQpharm Group · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks. The rationale for this open-label study is to assess the efficacy in preventing regain of loss body weight and safety of Glucosanol in subjects who are overweight or obese over a longer period after the initial weight loss.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DEVICE	Glucosanol	2 tablets taken 3 times a day.

Timeline

• Start date: 2011-09-01
• Primary completion: 2012-05-01
• Completion: 2012-07-01
• First posted: 2011-09-16
• Last updated: 2012-07-27

Locations

1 site across 1 country: Germany